

Krakow, 26th March 2024

REQUEST FOR PROPOSAL No. ABM-26032024A

In connection with the implementation by Ryvu Therapeutics S.A. of the project "The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent" no. 2022/ABM/06/00002/P/02 (hereinafter: "Project") co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6, Ryvu Therapeutics S.A. invites proposals for the execution of the following defined description of the order.

I. ORDERING PARTY/SPONSOR

Ryvu Therapeutics S.A.
Sternbacha 2, 30-394 Krakow, Poland
EU VAT PL6792942955

II. DESCRIPTION OF THE ORDER

This order concerns the execution of the **RNAseq of human samples** in the phase II clinical study of a study drug in combination with a market drug in patients with AML.

Service: RNAseq of human samples

STEP 1. RNA sample QC.

After QC, it is Ryvu who decides whether to proceed with RNAseq. We would like to ensure the possibility to proceed even though QC may fail due to low RNA amounts.

If we decide not to proceed we pay only for QC.

STEP 2. Human mRNA sequencing

Technology: Sequencing by synthesis (SBS) incorporating patterned flow cell technology.

Parameters: PE150; Q30>=85% cDNA directional library preparation (poly-A library) and sequencing 30M PE reads = 9GB data per sample

Timelines: 2 weeks starting from QC (from decisions after QC)

Data delivery via online cloud.

Ryvu is organizing and paying for the delivery of the package (samples).

The minimum number of experiments to be performed during the contract period (number of samples to be tested) is 2.

Estimated number of experiments to be performed during the contract period (number of samples to be tested) is 12.

II.2. Rules of order execution

- **CONTRACT TERM:** Deadline for performance of the contract: 31st May 2024.
In the event of prolonging the completion date of the Project stage, the agreement may be extended following changes in the Project co-financing agreement.
- **OFFER VALIDITY PERIOD:** at least until 30st April 2024.
- **ORDER COMPLETION DATE (TURNAROUND TIME):** up to 14 calendar days after QC decisions.
The execution of orders under the contract must take place within max. period given below. The turnaround time is an admission condition, proposal indicating a longer deadline for performance will be rejected.

III. PLACE, DATE PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

III.1. The proposal must be submitted by: **2nd April 2024.**

III.2. The proposal must be sent via e-mail to the following address: tenders@ryvu.com. The message with the proposal should refer to the RFP number indicated on the first page: **ABM-26032024A.**

III.3. The proposal and its attachments must be prepared in English or Polish.

- III.4.** The proposal should be prepared in an accordance with the form constituting Appendix 01 to this RFP.
The Bidders must provide the price for the service for 1 sample and the price the execution of the scope of the contract (total price for service for 12 samples).
- IV. ADDITIONAL INFORMATION**
- IV.1.** The Ordering Party allows for the possibility of awarding to the Contractor supplementary orders, in an amount not exceeding 50% of the value of the contract specified in the agreement concluded with the contractor, while such orders are consistent with the subject of the basic contract.
- IV.2.** The terms and conditions of the agreement may change during the course of the agreement (Ordering Party reserves the right to amend the agreement):
- in terms of the timelines and term of the agreement – following changes in the scope of the study and Project (extension of the duration of the Project, extension of appropriate stages of the Project, change of research plans);
 - in the event of force majeure as an event which is externally impossible to foresee and which could not have been prevented and whose consequences and effects could not have been prevented.
- IV.3.** The Bidders may ask the Ordering Party to clarify the content of the RFP. If the request for clarification of the content of the RFP was received later than by the end of 29th March 2024, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: tenders@ryvu.com.
- IV.4.** The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.
- IV.5.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of proposals for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the proposal sent by the Bidder.
- IV.6.** This RFP serves to estimate the market price of the contract (of 12 samples to be entirely tested). The Ordering Party reserves the right to enter into negotiations with Bidders who have submitted a proposal and meets the conditions for participating in the proceedings. Arrangements regarding the date of negotiations will be carried out by e-mail. The modified proposal may not contain conditions less favorable than the original proposal.
- IV.7.** This RFP does not oblige the Ordering Party to conclude a contract.
- IV.8.** For more information, please contact Anna Dziejzicka at the following email address: tenders@ryvu.com.

ATTACHMENTS

Appendix 01 – Proposal Form

APPENDIX 01 TO RFP no. ABM-26032024A
THE PROPOSAL FORM

Data of the Bidder Name:	
Address:	
Tax ID/EU VAT:	
Person authorized to contact the Ordering Party: name and surname:	
e-mail address:	

	Answer / confirmation of compliance *- delete inappropriate	Comments, if any
<p>Compliance of the offered service with the description of the subject of the order given in RFP:</p> <p>RNAseq of human samples <u>STEP 1.</u> RNA sample QC. After QC, it is Ryvu who decides whether to proceed with RNAseq. We would like to ensure the possibility to proceed even though QC may fail due to low RNA amounts. If we decide not to proceed we pay only for QC.</p> <p><u>STEP 2.</u> Human mRNA sequencing Technology: Sequencing by synthesis (SBS) incorporating patterned flow cell technology. Parameters: PE150; Q30>=85% cDNA directional library preparation (poly-A library) and sequencing 30M PE reads = 9GB data per sample Timelines: 2 weeks starting from QC (from decisions after QC) Data delivery via online cloud.</p>	YES/NO*	
<p>CONTRACT TERM: Deadline for performance of the contract: 31st May 2024. In the event of prolonging the completion date of the Project stage, the agreement may be extended following changes in the Project co-financing agreement.</p>	YES/NO*	
<p>OFFER VALIDITY PERIOD: at least until 30th April 2024.</p>	YES/NO*	
<p>ORDER COMPLETION DATE (TURNAROUND TIME): up to 14 calendar days after QC decisions. The execution of orders under the contract must take place within max. period given below. The turnaround time is an admission condition, proposal indicating a longer deadline for performance will be rejected.</p>	YES/NO*	
NET PRICE of performing <u>one experiment</u> including all costs (step 1 and step2)		
NET PRICE of performing <u>QC for 1 sample – only step 1</u> (price if Ordering Party decides not to proceed with <u>sequencing</u>)		
TOTAL NET PRICE of performing 12 experiments including all costs (step 1 and step 2 from Description of the order) = estimated value of the contract that serves to estimate the market price		

We confirm that the scope of the service offered is consistent with the subject of the request of the RFP no. ABM-26032024A.

.....
Place and date

.....
Signature of the authorized person